Clinical relevance of circulating tumor cells, ctDNA and diagnostic leukapheresis in pancreatic ductal adenocarcinoma patients

Clinical relevance of circulating tumor cells, ctDNA and diagnostic leukapheresis in pancreatic ductal adenocarcinoma patients - CTC and ctDNA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023362

Enrollment

Registered

2021-03-26

Start date

2019-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25

Interventions

Group 1: Observational trial: The blood draw takes place during routine blood draws perioperatively and during follow-up. No additional portal vein punctures are necessary, as blood is taken from rese

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: consent, PDAC, resectable

Exclusion criteria

Exclusion criteria: no consent, other than PDAC, not resectable

Design outcomes

Primary

Measure	Time frame
The overall aim of the study is to establish liquid biopsy protocols for PDAC patients in order to enable a more detailed molecular characterization of the disease and performance of functional test such as drug testing on the cells in the future.	—

Secondary

Measure	Time frame
KRAS Hot spot Mutation analysis, 24months follow up, WGS of single cells, cfDNA quantities, CTC counts, portal vein vs. peripheral vein	—

Countries

Germany

Contacts

Public ContactChristine Nitschke

Klinik für Allgemein-, Viszeral- und Thoraxchirurgie; Universitätsklinikum Hamburg-Eppendorf

c.nitschke@uke.de04074100

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026